Cargando…

Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18–64 years in the USA

INTRODUCTION: Intravenous tissue plasminogen activator (IV tPA) is a globally recommended treatment for patients with acute ischaemic stroke. We examined IV tPA use among patients aged 18–64 years with a primary diagnosis of acute ischaemic stroke in the USA and inpatient costs per hospitalisation b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joo, Heesoo, Wang, Guijing, George, Mary G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990217/ https://www.ncbi.nlm.nih.gov/pubmed/27547449 http://dx.doi.org/10.1136/svn-2015-000002

Ejemplares similares

A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischaemic stroke
por: Joo, Heesoo, et al.
Publicado: (2017)

Age-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke
por: Joo, Heesoo, et al.
Publicado: (2017)

Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis
por: You, Shoujiang, et al.
Publicado: (2018)

Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review
por: Wang, Xia, et al.
Publicado: (2018)

Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?
por: Dong, Yi, et al.
Publicado: (2016)

Intravenous tissue plasminogen activator, ischemic stroke, and the risk of Kounis Syndrome
por: Kounis, Nicholas G., et al.
Publicado: (2011)

DEPRESSION AND MEDICAL COST OF CARDIOVASCULAR DISEASES
por: Wang, Guijing, et al.
Publicado: (2019)

Ischaemic stroke and the recanalization drug tissue plasminogen activator interfere with antibacterial phagocyte function
por: Vogelgesang, Antje, et al.
Publicado: (2017)

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
por: Wardlaw, Joanna M, et al.
Publicado: (2012)

Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: a systematic review and meta-analysis
por: Guo, Yijia, et al.
Publicado: (2018)

Economic Burden of Informal Caregiving Associated With History of Stroke and Falls Among Older Adults in the U.S.
por: Joo, Heesoo, et al.
Publicado: (2017)

Unruptured Cerebral Aneurysm Detected after Intravenous Tissue Plasminogen Activator for Stroke
por: Yoneda, Yukihiro, et al.
Publicado: (2009)

Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review
por: Bhatt, Archit, et al.
Publicado: (2013)

Intravenous Tissue Plasminogen Activator for an Ischemic Stroke with Occult Double Primary Cancer
por: Yoneda, Yukihiro, et al.
Publicado: (2014)

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
por: Matsuo, Ryu, et al.
Publicado: (2014)

A Systematic Review of Economic Evidence on Community Hypertension Interventions
por: Zhang, Donglan, et al.
Publicado: (2017)

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
Publicado: (2012)

Outcomes of Endovascular Mechanical Thrombectomy and Intravenous Tissue Plasminogen Activator for the Treatment of Vertebrobasilar Stroke
por: Brinjikji, Waleed, et al.
Publicado: (2014)

Intravenous Tissue Plasminogen Activator Improves the Outcome in Very Elderly Korean Patients with Acute Ischemic Stroke
por: Choi, Jay Chol, et al.
Publicado: (2015)

Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers
por: Aparicio, Hugo J., et al.
Publicado: (2015)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016)

Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator
por: Chenna, Vijay, et al.
Publicado: (2018)

Intravenous tissue plasminogen activator for ischemic stroke in early pregnancy dosed by actual body weight
por: Peksa, Gary D, et al.
Publicado: (2019)

Cost-effectiveness of recombinant tissue-type plasminogen activator for acute ischaemic stroke with unknown time of onset: a Markov modelling analysis from the Chinese and US perspectives
por: Zhao, Songfeng, et al.
Publicado: (2022)

Intravenous thrombolysis in the emergency department for the treatment of acute ischaemic stroke
por: Semplicini, A, et al.
Publicado: (2008)

The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke
por: Dong, Qiang, et al.
Publicado: (2017)

Acute myocardial infarction following intravenous tissue plasminogen activator for acute ischemic stroke: An unknown danger
por: Sweta, Adatia, et al.
Publicado: (2010)

Imaging Evidence for Cerebral Hyperperfusion Syndrome after Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Zhang, Yi, et al.
Publicado: (2016)

ISCHAEMIC STROKE, PREVENTABLE WITH TISSUE ADHESIVE
por: Bothma, Pieter, et al.
Publicado: (2023)

Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis in a Patient with Acute Ischemic Stroke Secondary to Aortic Dissection
por: Hong, Keun-Sik, et al.
Publicado: (2009)

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
por: Chapman, Sherita N, et al.
Publicado: (2014)

Does Intravenous Administration of Recombinant Tissue Plasminogen Activator for Ischemic Stroke can Cause Inferior Myocardial Infarction?
por: Almasi, Mostafa, et al.
Publicado: (2016)

Carotid Artery Stenting for Acute Ischemic Stroke Patients after Intravenous Recombinant Tissue Plasminogen Activator Treatment
por: Deguchi, Ichiro, et al.
Publicado: (2016)

Different Doses of Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: A Network Meta-Analysis
por: Li, Bing-Hu, et al.
Publicado: (2022)

Recanalization Rate and Clinical Outcomes of Intravenous Tissue Plasminogen Activator Administration for Large Vessel Occlusion Stroke Patients
por: Lee, Min-Hyung, et al.
Publicado: (2023)

Emergent Double-barrel Bypass Shortly after Intravenous Administration of Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Choi, Joon-Ho, et al.
Publicado: (2016)

The Utility of Automated ASPECTS in Acute Ischemic Stroke for Intravenous Recombinant Tissue Plasminogen Activator (IV-rtPA) Therapy
por: Shibata, Soichiro, et al.
Publicado: (2022)

Comparing the Effectiveness of Intravenous Tissue Plasminogen Activator and Dual Antiplatelet Therapy in Patients With Minor Stroke: A Meta-Analysis
por: Monday, Obinna, et al.
Publicado: (2023)

Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape
por: Ganti, Latha, et al.
Publicado: (2022)

Management of Pediatric Strokes With Alteplase (Tissue Plasminogen Activator)
por: Filatov, Asia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ssclgpc4dh8n1se4shu70e7sie